Immunovant's batoclimab missed key Phase III endpoints in thyroid eye disease trials, and the stock slipped 2.4% on the news. Safety remained stable and there were signs of biological activity, but failure to meet primary endpoints is modestly negative for the drug's efficacy and the company's development outlook.
Immunovant's batoclimab missed key Phase III endpoints in thyroid eye disease trials, and the stock slipped 2.4% on the news. Safety remained stable and there were signs of biological activity, but failure to meet primary endpoints is modestly negative for the drug's efficacy and the company's development outlook.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly negative
Sentiment Score
-0.30
Ticker Sentiment
